Article Text

Download PDFPDF
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma
  1. Hiroyuki Fujiwara, MD, PhD*,
  2. Harushige Yokota, MD, PhD,
  3. Bradley Monk, MD,
  4. Isabelle Treilleux, MD§,
  5. Mojgan Devouassoux-Shisheboran, MD,
  6. Alison Davis, MD,
  7. Jae-Weon Kim, MD, PhD#,
  8. Sven Mahner, MD**,
  9. Michael Stany, MD,,
  10. Sandro Pignata, MD,,
  11. Isabelle Ray-Coquard, MD, PhD§ and
  12. Keiichi Fujiwara, MD, PhD§§
  1. *Jichi Medical University, Shimono-City, Japan and GOTIC;
  2. Saitama Cancer Center, Saitama-City, Japan and GOTIC;
  3. University of Arizona, Phoenix, AZ and GOG;
  4. §Centre Leon Berard, Lyon, France and GINECO;
  5. Hospices Civils de Lyon, Lyon, France and GINECO;
  6. The Canberra Hospital, Canberra, Australia and ANZGOG;
  7. #Seoul National University College of Medicine, Seoul, Korea and KGOG;
  8. **Universtatsklinikum Hamburg-Eppendorf, Hamburg, Germany and AGO;
  9. ††Walter Reed National Military Medical Center, Bethesda, MD and GOG;
  10. ‡‡Istituto Nazionale Tumori “Fondazione G. Pascale” – IRCCS, Milan, Italy and MITO; and
  11. §§Saitama Medical University International Medical Center, Hidaka-City, Japan and GOTIC.
  1. Address correspondence and reprint requests to Keiichi Fujiwara, MD, PhD, Saitama Medical University International Medical Center, Hidaka-City, Japan. E-mail: fujiwara{at}saitama-med.ac.jp.

Abstract

Cervical adenocarcinoma is known to be less common than squamous cell carcinoma of the cervix comprising approximately 25% of all cervical carcinomas. Differences in associated human papillomavirus types, patterns of spread, and prognosis call for treatments that are not always like those for squamous cancers. In this review, we report a consensus developed by the Gynecologic Cancer InterGroup surrounding cervical adenocarcinoma for epidemiology, pathology, treatment, and unanswered questions. Prospective clinical trials are needed to help develop treatment guidelines.

Key points Differences between adenocarcinoma and squamous cell carcinoma, and

Individualization of the therapy

  • Cervical Cancer
  • Adenocarcinoma
  • Pathology
  • Staging
  • Clinical management

Statistics from Altmetric.com

Footnotes

  • Isabelle Ray Coquard, MD has served on the board of, and received grant funding from, Roche Pharmaceuticals. She has also received payment for lectures from Amgen. Bradley J. Monk, MD has served as a consultant for Qiagen, GlaxoSmithKline, Merck, Arno Therapeutics, Insys Therapeutics, Tesaro, Celgene, Boehringer Ingelheim, and Roche/Genentech. He has also received grant funding from Novartis, Amgen, Genentech, Eli Lilly and Company, Janssen Pharmaceuticals/Johnson & Johnson, Array BioPharma, and Tesaro, and has received payment for lectures from Roche/Genentech and Johnson & Johnson. Keiichi Fujiwara, MD, PhD has served as a consultant for Zeria Pharmaceutical, GlaxoSmithKline, and Eisai, and has received payment for lectures from Taiho Pharmaceutical and Janssen Pharmaceuticals. The remaining authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.